影响CFTR中相同氨基酸的两种罕见变异对ivacaftor有不同的反应
Hongyu Li1, Mayuree Rodrat1,2, Majid K Al-Salmani1,3
1School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK.
两个囊性纤维化跨膜导电性调节器 (CFTR) 变体,S1159F和S1159P,损害了通道门并降低了功能. 伊瓦卡夫托强化了这些变异,但也减少了电流流量,这表明需要组合疗法来实现最佳的CFTR功能.
科学领域:
- 分子生物学分子生物学
- 离子通道生理学 离子通道生理学
- 遗传疾病 遗传疾病
背景情况:
- 囊性纤维化 (CF) 是由CFTR基因的突变引起的.
- CFTR变异S1159F和S1159P影响相同的残留物,并与不同的临床表型相关.
- 了解这些变体的分子机制对于开发向疗法至关重要.
研究的目的:
- 调查CFTR变异S1159F和S1159P的功能后果.
- 阐明 ivacaftor 对这些CFTR变异的功能的影响.
- 确定CFTR变异组合疗法的治疗潜力.
主要方法:
- 在中国仓鼠卵巢细胞中CFTR变异的异质表达.
- 补丁电生理学研究单通道行为.
- 对通道封闭,导电性和对 ivacaftor 的反应进行分析.
主要成果:
- S1159F和S1159P CFTR变种降低了单通道导电量,并严重减弱了通道门,降低了开放概率.
- 与S1159P-CFTR相比,S1159F-CFTR在开放概率上表现出更大的降低,与更严重的临床表型相关.
- 伊瓦卡夫托尔增强了两种变体的关口,但也减少了电流流量,特别是在S1159F-CFTR的较高度下.
结论:
- S1159F和S1159P变种通过多种机制导致CFTR功能障碍,包括受损的门和改变的导电.
- 伊瓦卡夫托尔对关门强化和电流减少的双重效应强调了需要量身定制的治疗策略.
- 针对不同CFTR缺陷的组合疗法是必要的,以完全恢复这些变体的通道活性.
更多相关视频
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
09:59Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein
Published on: March 9, 2015
相关概念视频
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...
Comparing Copy Number Variations and SNPs
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Protein Complexes with Interchangeable Parts
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
Mutations
Pleiotropy
